DNA methylation is essential for embryonic development and important for transcriptional repression, as observed in several biological phenomena. These include genomic imprinting, X-inactivation and carcinogenesis. The basic mechanism by which DNA methlyation silences transcription is generally understood, but there is still much to be learned about how DNA methyltransferase is targeted to a specific region of the gene. Silencing by DNA methylation occurs at an early stage of carcinogenesis, when the DNA repair genes, MGMT and hMLH1, are frequently inactivated, resulting in mutations in key cancer-related genes in cells. Mice defective in Mgmt and/or Mlh1 gave clear evidence of the significant roles of these proteins in carcinogenesis.
Introduction
Epigenetics is the study of mitotically and/or meiotically heritable changes in gene function that cannot be explained by changes in DNA sequence (Russo et al., 1996) . For convenience, epigenetics can be classified into two types: one is dependent on DNA methylation and the other is not. DNA methylation is the major epigenetic modification of the mammalian genome, now widely accepted as being important in the regulation of gene expression in mammals as well as in higher plants. The major modified base in DNA methylation is 5-methylcytosine (m 5 C) within a CpG dinucleotide. The CpG dinucleotide is mainly localized in the CpG islands, which are distributed in promoter regions of certain genes. DNA methylation is associated with changes in chromatin structure; consequently, gene silencing is achieved through interference in transcription. The significance of DNA methylation-independent epigenetics, such as histone acetylation/deacetylation and histone methylation, has recently been recognized. Current studies suggest that DNA methylation is indirectly linked with histone methylation (Tamaru and Selker, 2001; Jackson et al., 2002) .
In cancer, many critical genes are aberrantly silenced by DNA methylation. Recent studies have shown that silencing of certain DNA repair genes by DNA methylation might be related to the occurrence of tumorigenic mutations. Among mismatch repair genes, whose defects would cause tumor-prone genetic diseases, MLH1 frequently loses its potential through lowered levels of gene expression, due to hypermethylation of its promoter region. Epigenetic silencing is also observed with the Mgmt gene, whose product repairs the promutagenic DNA lesion O 6 -methylguanine. These alterations have been widely observed in human tumors (Esteller et al., 2000a (Esteller et al., , 2001a Jones and Baylin, 2002; Baylin et al., 2001) . Thus, arriving at a solid understanding of the mechanisms underlying gene silencing is of utmost importance in carcinogenesis as well as mutagenesis.
Here we describe first the general features of gene silencing through DNA methylation, and then proceed to the problems related to loss of expression of DNA repair genes.
Mechanism of gene silencing by DNA methylation

DNA methylation in various biological phenomena
Differential expression takes place through normal development, and a part of the process is related to tissue-specific expression after differentiation, imprinting, and X-inactivation. It is well known that DNA methylation is involved in these phenomena. In addition, aberrant DNA methylation is frequently observed in cancer, in which expression of certain genes is greatly altered. While global DNA hypomethylation occurs in wide areas of chromosomes, inactivation of genes in tumor cells occurs regionally in non-random fashion in certain localized areas of chromosomes and contributes to establishing cancer phenotypes. Another biological role of DNA methylation is prevention of expression of parasitic DNA elements, such as retrotransposons, retroviruses, and some repetitive elements, limiting their spread through the genome. Here we will discuss general features of gene expression, including tissue-specific expression, imprinting, and X-inactivation and then proceed to silencing of DNA repair genes.
Tissue-specific expression has long been speculated to be controlled by DNA methylation. However, no genes responsible for the DNA methylation process have been identified. Although some candidate genes were isolated, gene targeting experiments for DNA methyltransferase have failed to support their roles in regulation of tissue-specific genes (Walsh and Bestor, 1999) . Recently, some other candidate genes have been described (de Smet et al., 1999; Futscher et al., 2002) , and further studies are awaited.
Genomic imprinting is a functional non-equivalence of the parental genome and results in the expression of gene from only one of the two parental chromosomes (Reik and Walter, 2001 ). This phenomenon is an epigenetic marking by which expression of imprinted genes becomes dependent on their parental origin. Many of these genes play key roles in growth, differentiation and behavior. The primary mechanism of genomic imprinting is thought to be CpG methylation (Reik and Walter, 2001 ). Since only one of the parental alleles is methylated, this type of methylation is allele specific. The region for differential methylation is usually referred to as 'DMR' (differentially methylated region), which is a hallmark of imprinted genes . If methylation in DMR originates from a germ cell, this region is called an imprinting center (IC) (Ben-Porath and Cedar, 2000) . Targeting experiments of candidate ICs, derived from the mouse counterpart corresponding to human imprinted region, showed loss of imprinting of those regions (Wutz et al., 1997; Thorvaldsen et al., 1998; Yang et al., 1998) . Recently, it was revealed that histone modifications are important to determine whether the DNA methylation occurs (Tamaru et al., 2001; Jackson et al., 2002) . It is proposed that histone methylation at lysine 9 is a gametic imprint in the imprinting center PWS-IC (Xin et al., 2001) , while cytosine methylation of the PWS-IC occurs only after fertilization (El-Maarri et al., 2001) .
X-chromosome inactivation in mammals is the means for dosage compensation of X-linked genes, which is achieved by transcriptional silencing of genes on one of the two X chromosomes in the female . Xist RNA, which is specifically transcribed in inactive X, is produced after differentiation. This RNA product is spread and coats its own chromosome to establish the inactive state. To achieve this, histone deacethylation and DNA methylation of X-linked genes, as well as the recruitment of the histone variant macroH2A, occur and presumably assist in transforming the Xist RNA-coated chromosome into a stably inactive and condensed chromatin state. Recent studies show that methylation of histone, particularly of H3, is important to mark the inactive X; namely, H3 methylation provides an epigenetic imprint or a nucleation center for Xist RNA on the inactive X . Furthermore, the inactive X chromosome is enriched for H3 methylated at lysine 9 (H3-K9) (Boggs et al., 2002; Peters et al., 2002) . It has also been demonstrated that histone methylation occurs prior to DNA methylation of CpG island (Brockdorff, 2002) .
How does DNA methylation repress the target gene?
CpG islands rich in CpG sequences are found in promoter regions of half of the genes in the mammalian genome and are usually unmethylated in normal cells, except for genes observed in some biological phenomena related to gene silencing. The direct correlation between CpG island methylation and silencing of gene transcription is as follows (Santini et al., 2001) : (1) cells in which silencing occurs are usually transcriptionally competent for the affected gene if this gene is unmethylated; (2) demethylation by pharmacologic agents results in reactivation of gene expression (Jones, 1985) ; and (3) in vitro methylation substantially reduces gene expression in transfection assay.
The process of inhibition of transcription was initially thought to be simply due to physical interference when the methyl group protruded into the major groove and in consequence lowered levels of association with the transcriptional apparatus (Tate and Bird, 1993) . However, it was revealed that the inhibitory mechanism exerts its effect through the binding of specific proteins to the methylated DNA sequences. The responsible protein, MeCP2, was identified (Lewis et al., 1992) , and subsequently an additional four proteins were found in mammals. These proteins commonly possess a methylCpGbinding domain, and were named MBD1 through MBD4 (Hendrich and Bird, 1998) . MethylCpG-binding proteins (MBDs), MeCP2 and MBD1 through MBD4, belong to MBD family members. MeCP2 and MBD1 have a transcriptional repressor domain (TRD), to which the corerepressor mSin3A would bind. This corerepressor protein constitutes the core of a multiprotein complex, in which histone deacetylase is included. It turned out that the mechanism by which DNA methylation could inhibit transcription was due to sterical blocking of transcription factors by binding the MBDs.
The process of transcriptional repression by DNA methylation is illustrated in Figure 1 . DNMT recruited by unknown DNA binding protein methylates DNA, while this DNMT interacts with HDACs ( Figure 1a ) Fuks et al., 2000; Rountree et al., 2000) . DNMT can thereby act as a repressor by methylating CpG sites and simultaneously by being associated with histone deacethylation. Then, one of MBDs binds tightly to chromosomes in a methylationdependent manner. TDR, one of the binding domains of MBDs, associates with histone deacetylase to form deacetylated histone (Jones et al., 1998; Nan et al., 1998) (Figure 1b ). This deacetylation of histone (and/or other proteins) is an essential component of this repression mechanism, since transcriptional repression in vivo is relieved by a deacetylase inhibitor, tricostatin A.
How does DNMT target some specific regions of the chromosome?
DNA methylation does not occur randomly in a genome DNA. Methylation can be targeted in vivo within certain regions of the chromosomes where repetitive DNA elements, centromeres, and imprinted genes exist. In tumor cells, this methylation is aberrantly targeted to impair expression of tumor suppressor genes. For methylation, DNA methyltransferase (DNMT) has to be recruited to a targeting site on the gene promoter.
DNMT1-containing fraction with deacetylase activity, isolated from HeLa cell, contained HDAC1, the tumor-suppressor protein Rb and the sequence-specific transcriptional activator E2F1 . This complex is capable of repressing transcription from promoters containing E2F1-binding sites. The role of this complex in targeting methylation to a specific region of the gene was established by the following experiment (Figure 2 ).
PML -RAR, an oncogenic transcription factor found in acute promyelocytic leukemias (APL), is a fusion protein of the promyelocytic leukemia (PML) protein with retinoic acid receptor (RAR) and functions as a transcriptional regulator of retinoic acid (RA)-responsible genes. Using this PML -RAR, di Croce et al. (2002) examined whether PML -RAR is responsible for CpG methylation of its target genes and whether aberrant methylation is relevant for its biological activity. When applied to the RA receptor RARb2, which contains a CpG island and is considered to be a putative tumor suppressor, PML -RAR bound to the RARb2 promoter and induced its transcriptional silencing. Methylated sites on the APL samples were located near the promoter and exon 1 regions, and physical association between PML -RAR and endogenous DNMT1 and DNMT3a was evident. Furthermore, DNMTs were enriched at the RARb2 promoter in the presence of PML -RAR, demonstrating that PML -RAR and DNMTs form a stable complex on the RARb2 promoter ( Figure 2a ). Treatment with RA and 5-Aza-dC induced promoter demethylation, thereby resulting in reactivation of the gene expression, and, consequently, reversion of the transformed phenotype (Figure 2b ). This is the first case demonstrating targeting methylation to a specified sequence. There is another example to show that DNMT3a can be targeted to promoter through its association with a sequence-specific transcription factor, RP58 (Fuks et al., 2001 ). This RP58 is a The core histone tails are susceptible to a variety of covalent modifications, including acetylation, phosphorylation, methylation, and ubiquitination. These modifications may be critical for transcriptional and translational regulation (Zhang and Reinberg, 2001 ). Based on this, 'histone code' hypothesis has been proposed Jenuwein and Allis, 2001) .
Methylation of histone H3 and H4 is important in this process, and we focus here on methylation of the lysine 9 residue in histone H3 (H3-K9), since it could be linked to DNA methylation. SUV39H1/Suv39h1 gene encodes histone H3-specific methyltransferase (HMTase) that methylates lysine 9 of the amino terminus region of histone H3 (Rea et al., 2000) . H3-K9 was selectively recognized by the chromo domain of HP1 (heterochromatin protein 1) Lachner et al., 2001) (Figure 3a) . HP1 is then localized in the heterochromatin region, where gene silencing occurs. Thus, the chromo domain of HP1 is necessary for both targeting H3-K9 and transcriptional repression. Although interaction between HP1 and HMTase was initially found in the heterochromatic region, this interaction has also been observed in the euchromatic region (Nielsen et al., 2001) . It seems that HMTase enzymes are able to discriminate between the heterochromatic and the euchromatic region. At least four different types of HMTases, SUV39H1/Suv39h1, G9a, SETDB1/ESET and Eu-HMTase1, are presently known (Rea et al., 2000; Tachibana et al., 2001; Schultz et al., 2002; Yang et al., 2002; Ogawa et al., 2002) . SUV39H1/Suv39h1 enzyme might act on heterochromatin to repress the pericentric heterochromatin region, while the remaining three might target transcriptionally active sites of the euchromatin regions.
Further insight on this process was recently reported with fungi as well as with plants. Tamaru et al. (2001) demonstrated that replacement of H3-K9 with either leucine or arginine residue induced a markedly reduced level of DNA methylation in Neurospora crassa, indicating that DNA methylation depends on histone methylation (Figure 3b ) (Tamaru et al., 2001) . A similar observation was made with Arabidopsis thaliana (Jackson et al., 2002) . However, how histone methylation regulates CpG methylation is not known.
These results indicate that a causal relationship between histone methylation and DNA methylation is conserved throughout eukaryotes. Recruitment of DNA methyltransferase to chromatin by HP1 could be a general eukaryotic phenomenon, as evidenced by a recent study with mouse. Expression of the mouse Mage-a2 gene is controlled by DNA methylation and usually turned off in most tissues, except for testis (de Smet et al., 1999) . In G9 +/+ ES cells, H3-K9 is enriched in the chromatin containing the Mage-a2 promoter sequence, while its content is severely reduced in G9a 7/7 ES cells, suggesting that DNA methylation will be lost by depletion of G9a HMTase in G9a 7/7 (Tachibana et al., 2002) .
Silencing of DNA repair genes
General aspects of gene silencing by DNA methylation in cancer
Two hits are required for the full inactivation of a tumor-suppressor gene (Knudson, 1971) , and this is usually achieved by a mutation in one allele and loss of heterozygosity in another allele. Jones and Laird (1999) pointed out that many tumor-suppressor genes are inactivated by DNA methylation at considerable frequencies, and methylation of one allele with coordination of mutation or LOH in another-allele, or methylation of both alleles, would cause the same effect.
Genes affected by DNA methylation in cancer are presented in 'Genes affected by promoter CpG island methylation in aging and/or cancer' (www3.mdanderson. org/leukemia/methylation/cgi.html). Approximately 70 genes are listed, which include genes related to cellcycle control, DNA repair, apoptosis, and metastatic How widespread is DNA hypermethylation in tumor cells? The restriction landmark genome scanning (RLGS) is a suitable method for such global analysis (Hatada et al., 1991) . It was estimated that approximately 600 CpG islands (13%) of the 45 000 in the genome are aberrantly methylated in tumors (Antequera and Costello et al., 2000) . The patterns of CpG island methylation are non-random and show distinct tumor-type specificities, suggesting that each tumor may display a distinguishable methylation subtype in the genome.
Gene hypermethylation profiles for a total of 12 genes in human cancer have been provided, which were derived from 600 specimens of primary tumors of 15 tissues (Esteller et al., 2001b) . From this analysis, the following features of human tumors have been derived. First, profiles of promoter hypermethylation differ for each cancer type, providing tumor-type and genespecific profiles. This is consistent with the result obtained by the RLGS method (Costello et al., 2000) . Second, epigenetic inactivation may affect all of the molecular pathways involved in cell immortalization and transformation. Third, these epigenetic changes occur in the absence of a genetic lesion and also biallelically if coding sequences are wild type (Herman et al., 1995; Esteller et al., 2000b; Veigl et al., 1998) . Finally, it seems that epigenetic changes are one of several early steps in carcinogenesis (Belinsky et al., 1998; Esteller et al., 1999 Esteller et al., , 2000b Fleisher et al., 2000) .
Of genes related to DNA repair, hMLH1 and MGMT draw a special attention concerning aberrant DNA methylation in cancer. Human DNA mismatch repair genes (hMLH1, hMSH2, hPMS1 and hPMS2) are known as the cause of HNPCC (hereditary nonpolyposis colorectal cancer). Among them, hMLH1 exhibits a frequent occurrence of DNA hypermethylation, which is related to genetic instabilitymicrosatellite instability (Kane et al., 1997; Herman et al., 1998; Esteller et al., 1998) . As a consequence of loss of this gene function, mutations would accumulate in the genome. MGMT, on the other hand, is involved in repair of alkylated bases in DNA. Since O 6 -methylguanine, which can be repaired by the MGMT function, causes mutations leading to tumor induction, preservation of the function of this gene is important for preventing induction of tumors. These situations have been shown in an animal model, as described in the following section.
Animal models for lack of DNA repair genes Some human and rodent cell lines, particularly those derived from tumors, show an increased sensitivity to simple alkylating agents, such as N-methyl-N-nitrosourea (MNU) and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and yield more mutations when treated with relatively low doses of such agents (Day et al., 1979; Sklar and Strauss, 1981) . These cell lines were termed Mer -or Mex -and were further characterized by their lack or possession of a very low level of O 6 -methylguanine-DNA methyltransferase activity. This enzyme repairs promutagenic DNA lesion, O 6 -methylguanine and O 4 -methylthymine, which account for approximately 5 and 0.1% of the total alkylated DNA adducts, respectively (Koike et al., 1990) . Despite the lack of enzyme activity, Mer -cells show no gross alteration in coding and promoter regions of the Mgmt gene, encoding methyltransferase protein; therefore, the decreased levels of enzyme activity may be due to transcriptional silencing (Harris et al., 1991; Nakatsu et al., 1993) .
Cultivation of Mer -cells in the presence of certain low levels of alkylating agents yields alkylationresistant cells. Most of these cells are still deficient in methyltransferase activity, and the second alteration may have occurred to suppress the original high susceptibility to alkylating agents. Although molecular mechanisms underlying this phenomenon are not fully understood, most of these phenotypic revertants are devoid of mismatch repair activity (Branch et al., 1993; Kat et al., 1993) . Among several genes involved in mismatch repair, epigenetic silencing of the Mlh1 gene occurs most frequently. There is hypermethylation of CpG islands in promoter regions of Mgmt or Mlh1 genes in several cancer cell lines as well as in human carcinoma (Watts et al., 1997; Qian and Brent, 1997; Veigl et al., 1998; Deng et al., 1999; Danam et al., 1999; Esteller et al., 2000a) .
To clarify the roles of MGMT and MLH1 protein in carcinogenesis, mouse lines defective in either one or both of these genes were constructed using gene targeting techniques. Mice defective in the Mgmt gene are hypersensitive to the killing effect of alkylating agents (Tsuzuki et al., 1996) . In addition, a large number of tumors occurred in Mgmt 7/7 mice exposed to relatively low doses of MNU and dimethylnitrosoamine, whereas no or few tumors occurred in normal mice treated in the same manner Iwakuma et al., 1997) . Death of Mgmt 7/7 mice after MNU administration was closely related to bone marrow damage and dysplastic mucosae of intestines together with crypt abscesses. This severe myelosuppression led to a drastic decrease in the number of peripheral leukocytes and platelets (Tsuzuki et al., 1996) . Thus, methyltransferase has a vital role in protecting these organs from toxic effects of alkylating agents. It is notable that Mgmt 7/7 mice are considerably more sensitive to chemotherapeutic alkylating drugs, presently in clinical use, than are wild type mice (Glassner et al., 1999; Shiraishi et al., 2000) .
The killing and the tumorigenic effects of alkylating agents can be dissociated by introduction of a mismatch repair defect into methytransferase-deficient mice (Kawate et al., 1998) . Mice with mutations in both alleles of the Mgmt and the Mlh1 genes are as resistant to MNU as are wild type mice, in terms of survival, but do have numerous tumors after receiving MNU (Figure 4) . In contrast to Mgmt 7/7 Mlh1 +/+ mice with smaller thymus and hypocellular bone marrow after MNU administration, no conspicuous
Gene silencing in DNA repair T Mukai and M Sekiguchi change was found in Mgmt 7/7 Mlh1 7/7 mice treated in the same manner. Thus, introduction of a mismatch repair gene defect renders methyltransferase-deficient mice resistant to the lethal action of alkylating agents, still maintaining the high susceptibility to tumor formation. Such mice may be useful for evaluating carcinogenic effects of various substances, including those for therapeutic application.
In this context, there is a problem that these doubly deficient mice had a small but significant number of tumors even without exposure to MNU (see Figure 4) . This phenomenon is common to mice defective in mismatch repair (de Wind et al., 1998; Prolla et al., 1998) , and such a high incidence of tumors is characteristic of HNPCC patients defective in one of the mismatch repair genes (Leach et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994; Kolodner et al., 1995) .
This complexity was resolved by introducing the Mlh1 +/7 mutation, instead of Mlh1 7/7 , in the methyltransferase-deficient mice (Kawate et al., 2000) . mice had tumors, and there were no tumors in those mice not given the treatment (Figure 4 ). It seems that the cellular content of MLH1 protein is a critical factor for determining if damaged cells enter into the pathway leading to mutation induction or to apoptotic cell death. This situation is illustrated in a model shown in Figure 5 . At an early step in mismatch repair, four of the products of at least five genes, Msh2, Msh3, Msh6, Mlh1 and Pms2, form complexes and play an important role in recognition of mismatched pairs and initiation of repair reaction (Modrich and Lahhue, 1996; Papadopoulos and Lindblom, 1997; Jiricny, 1998) . It is generally assumed that a defect in any one of these genes would lead to defects in mismatch repair. In fact, mutations in these genes have been found in human HNPCC patients, though the frequencies of mutations in each of the genes were significantly different (Leach et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994; Kolodner et al., 1995) . Thus, there is a possibility that mutations in genes other than Mlh1 might lead to a similar phenotype observed with Mlh1 +/7 and Mlh1 7/7 mice. However, it was reported that after treatment with O 6 -benzylguanine, an inhibitor of O 6 -methylguanine methyltransferase, Msh2
+/7 cells were as sensitive as Msh2 +/+ cells to alkylating agents (de Wind et al., 1995) . This apparent difference may be due to different levels of expression of the genes or to different modes of action of these proteins.
Mlh1 expression in tumor tissues of Mgmt
Mlh1 +/7 mice exposed to MNU is heterozygous; four of 13 lymphoma samples analysed showed complete absence of MLH1 protein, whereas the remaining lymphoma cells contained half of the normal amount of MLH1 protein (Kawate et al., 2000) . PCR analyses of the DNA from those MLH1-deficient lymphomas revealed no deletion or large alteration in the wild-type Mlh1 allele. It may be that a base substitution was induced by MNU or that some modification occurred in a certain region of the gene, such as hypermethylation in the promoter region. Whatever the cause, this loss of Mlh1 expression might be related to transformation of the cell. A complete deficiency of MLH1 function would lead to an increased frequency of errors during DNA replication. It has been shown that some gene expression is altered during tumor development and such alterations in the genome would further accelerate progression of the tumor. Figure 4 Effects of MNU on tumor induction in mice with various genetic backgrounds. Mice (6 weeks old) were given 30 mg/kg of body weight of MNU or phosphate-buffered saline (control) i.p. and killed 8 weeks later for examination. Data were taken from Kawate et al. (1998 Kawate et al. ( , 2000 Most HNPCC patients have mutations in only one allele of certain mismatch repair genes, but frequently produce tumors (Leach et al., 1993; Bronner et al., 1994; Papadopoulos et al., 1994; Kolodner et al., 1995) . Some of these tumors are devoid of mismatch repair protein, a phenomenon similar to that observed in Mlh1 +/7 mice (Kawate et al., 2000) . Thus, alterations in the level of Mlh1 expression may be an important factor in determining genetic stability as well as susceptibility to carcinogens.
Epigenetic silencing observed with clinical samples
Among DNA repair genes, hMHH1, MGMT and BRCA1 most frequently exhibit epigenetic silencing. Thus, levels and extents of DNA methylation of these genes have been examined with special reference to gene and tumor types (Esteller et al., 2001b) . Tissues showing more than 20% of methylation in these genes are colon, lung, head and neck, lymphoma, brain, and esophagus in MGMT; colon, uterus, and stomach in hMLH1. In addition, tumor types are different, depending on the genes affected. The epigenetic lesion is often an early event. Both MGMT and hMLH1 showed DNA methylation even in precancerous tissues: MGMT in colorectal adenoma (Esteller et al., 2000b) and hMLH1 in endometrial hyperplasia (Esteller et al., 1999) and ulcerative colitis (Fleisher et al., 2000) .
In tumors of mice induced by DMNA (dimethylnitrosamine) and MNU, G : C to A : T transitions occur frequently in the K-ras gene (You et al., 1989; Chen et al., 1994) . Many clinical samples, derived from MGMT-deficient or MLH1-deficient cancers, were examined for such mutations in tumor-related genes. In the samples whose MGMT gene is hypermethylated, transition mutations were found frequently in both Kras and p53 genes of various cancers. Of colorectal cancer samples with transition mutations in the K-ras gene, 71% showed hypermethylation of MGMT (Esteller et al., 2000a) . In the case of p53, transition mutations were 64, 71, and 92% in non-small cell lung cancer, colorectal cancer, and astrocytomas (secondary glioblastomas), respectively (Esteller et al., 2001a; Wolf et al., 2001; Nakamura et al., 2001) . Recently, Rajagopalan et al. (2002) found that in colorectal cancers, Braf mutations occur only in tumors that do not carry mutations in the K-ras. There was a striking difference in the frequency of Braf mutations between cancers with and without mismatch repair deficiency: mismatch repair-deficient tumors had a very high incidence of Braf mutations and a lower incidence of K-ras mutations as compared with mismatch repairproficient colorectal cancers.
Referring to the results of Mgmt and Mlh1 double knockout mice (Iwakuma et al., 1997; Sakumi et al., 1997; Kawate et al., 1998 Kawate et al., , 2000 , it is of interest to note the expression levels of both MGMT and MLH1 genes in human cancers. We examined 46 samples of hepatocellular carcinomas by Western blot analysis to see MGMT and MLH1 expression deficiencies (Matsukura et al., 2003) . Twenty per cent of tumor samples showed hMLH1 deficiency, while 60% of them lacked MGMT expression. Of interest is the observation that 10% of these samples lacked both MGMT and MLH1 expression, implying that defective expression of these two genes occurs independently. This may be related to the observation that in colorectal cancers, MGMT and hMLH1 genes are inactivated at high incidence by hypermethylation (Esteller et al., 2001b) . 
Future prospect
Recent works in epigenetics has raised an important issue for DNA methylation. One of the major questions is whether DNA methylation is a primary cause of certain biological phenomena or a consequence of certain preceding events. It was naturally thought in the case of genomic imprinting that DNA methylation is a gametic imprint, since targeting of the Dnmt1 gene resulted in failure of imprinting, due to loss of maintenance methylation (Li et al., 1992) . However, recent studies in fungus and plant revealed that the histone H3-K9 mark is necessary for DNA methylation, indicating that histone methylation could be an upstream event for DNA methylation. In mammals, H3-K9 methylation is observed as an earliest known chromatin change during X-inactivation and is also required for genomic imprinting. In genomic imprinting, H3-K9 methylation occurs specifically on the inactive allele of imprinted gene in human. Targeting of the HMTase gene, G9a, also indicates that DNA methylation could be lost in Magea2, as described earlier. All these results strongly suggest that H3-K9 methylation is an epigenetic imprint, which could cause DNA methylation as a secondary event.
It is important to know whether DNA methylation is closely linked to histone methylation in cancer tissues. If this pathway is aberrantly regulated in tumor cells, we may observe a different relationship between these two processes. Further studies are clearly necessary to understand nature of DNA and histone modification in carcinogenesis and to develop therapeutic agents to intervene in these processes.
